Pharmacokinetics of once-daily lopinavir/ritonavir and the influence of dose modifications

AIDS

Volumn 19, Issue 10, 2005, Pages 1105-1107

  La Porte, Charles J L ^a   Schippers, Emile F ^b   Van Der Ende, Marchina E ^c   Koopmans, Peter P ^a   Blok, Willem L ^d   Kauffmann, Robbert H ^e   Kroon, Frank P ^b   Burger, David M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Ziekenhuis Walcheren   (Netherlands)

^e LEYENBURG HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; TENOFOVIR;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL;

EID: 21844468794     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000174459.93744.4a     Document Type: Article

References (9)

1. Eron JJ, Feinberg J, Kessler HA, Horowitz HW, Witt MD, Carpio FF, et al. Once-daily versus twice-daily lopinavir/ ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J Infect Dis 2004; 189:265-272.
2. Feinberg J, Eron J, Bernstein B, King M, Manning L, Bertz R, et al. Once-daily vs. twice-daily Kaletra (lopinavir/ritonavir) in antiretroviral-naive HIV+ patients: 72 week follow-up. In: XIVtH International AIDS Conference. Barcelona, Spain, 7-12 July 2002 [Abstract TuPeB4445].
3. Anonymous. Optimising TDM in HIV clinical care. A practical guide to performing therapeutic drug monitoring (TDM) for antiretroviral agents. 2003. Available at: http://www.HIVpharmacology.com. Site accessed: 2 March 2005.
4. Hsu A, Isaacson J, Brun S, Bernstein B, Lam W, Bertz R, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47:350-359.
5. Droste JA, Verweij-Van Wissen GM, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8 and nevirapine in human plasma by reversed phase high performance liquid chromatography. Therapeut Drug Monit 2003; 25:393-399.
6. Product information Kaletra®. Abbott, Chicago, IL, USA; 2000.
7. Breilh D, Rouzes A, Djabarouti S, Pellegrin I, Xuereb F, Coupet AC, et al. Pharmacokinetic drug interaction of lopinavir/ritonavir in combination with tenofovir in experienced HIV+ patients. In: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, 30 October-2 November 2004 [Abstract no. A-445].
8. la Porte CJL, Burger DM. Is nelfinavir (NFV) 1500 mg BID an effective intervention for patients on NFV 1250 mg BID who have low NFV exposure? In: 2nd International Workshop on Clinical Pharmacology of HIV Therapy. Noordwijk, the Netherlands, 2-4 April 2001 [Abstract 6.8].
9. Pharmaceutical Products Division, Research and Development, Abbott Laboratories. ABT-378 investigator brochure, edn 5. Abbott Park, Illinois 60064, USA; 4 May 2000.